SCHEMBL6762166

SCHEMBL6762166

CC(C)CCSc1ccccc1C=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
THRB P10828 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
MAOA P21397 2/20 0.39
MAOB P27338 2/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 3/20 0.38
TSHR P16473 1/20 0.38
HPGD P15428 2/20 0.35
HTT P42858 2/20 0.35
METAP2 P50579 1/20 0.35
TRIM24 O15164 1/20 0.34
TRIM33 Q9UPN9 1/20 0.34
CTSB P07858 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6759591 0.82 LMNA (0.43) LMNAMEN1THRBBLMKMT2A
SCHEMBL7760109 0.80 PTGS2 (0.47) LMNAMEN1THRBBLMKMT2A
SCHEMBL6759508 0.79 CA1 (0.45) SMN1; SMN2HTT
SCHEMBL6759510 0.79 CA1 (0.45) SMN1; SMN2HTT
SCHEMBL8595709 0.77 PTGS2 (0.51) LMNAMEN1THRBBLMKMT2A
SCHEMBL10364821 0.77 LMNA (0.44) LMNAMEN1THRBBLMKMT2A
SCHEMBL979786 0.77 MEN1 (0.44) LMNAMEN1THRBBLMKMT2A
SCHEMBL14279407 0.77 LMNA (0.44) LMNAMEN1THRBBLMKMT2A
SCHEMBL6765848 0.76 PTGS2 (0.51) LMNAMEN1THRBBLMKMT2A
SCHEMBL2801460 0.76 LMNA (0.48) LMNAMEN1THRBBLMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-09-30 US disclosed
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 LMNA 2027/4885MEN1 1311/4885THRB 1804/4885
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 LMNA 2027/4885MEN1 1311/4885THRB 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.